KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Gross Profit (2017 - 2025)

Historic Gross Profit for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $1.2 billion.

  • BeOne Medicines' Gross Profit rose 4627.84% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 5431.37%. This contributed to the annual value of $3.2 billion for FY2024, which is 5470.76% up from last year.
  • BeOne Medicines' Gross Profit amounted to $1.2 billion in Q3 2025, which was up 4627.84% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Gross Profit ranged from a high of $1.2 billion in Q3 2025 and a low of $113.7 million during Q2 2021
  • Over the past 5 years, BeOne Medicines' median Gross Profit value was $528.6 million (recorded in 2023), while the average stood at $566.0 million.
  • As far as peak fluctuations go, BeOne Medicines' Gross Profit surged by 141196.78% in 2021, and later plummeted by 5788.65% in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Gross Profit stood at $165.4 million in 2021, then skyrocketed by 85.31% to $306.6 million in 2022, then surged by 72.41% to $528.6 million in 2023, then surged by 82.99% to $967.3 million in 2024, then rose by 25.69% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.2 billion for Q2 2025, and $952.3 million during Q1 2025.